Credit: In collaboration with Florida Healthcare Law Firm
Patient safety belongs at the center of any GLP-1 discussion. But Lilly’s retatrutide lawsuit makes it difficult to separate the safety discussion from the commercial one. Lilly’s complaint against Striker Pharmacy makes a legal case against unauthorized retatrutide sales. Retatrutide remains investigational. No FDA-approved retatrutide product currrently exists, and FDA has said since at least since March 2025 that retatrutide cannot be used in compounding.
The business context is less clean. Lilly plans to submit a Biologics License Application for retatrutide in Q1 2027 while using state unfair competition and deceptive practices laws against an operator accused of selling the molecule before approval. It’s unclear how Lilly has the standing to bring claims re a chemical that isn’t yet FDA approved. How are they injured if they don’t even have the right to sell it yet? They will have to clear that hurdle. The case enforces the rules that apply today, but it also helps clear the field ahead of a potential retatrutide launch. In this way, it seems that Lilly’s latest suits are (at least in part) part of an early “ground and pound game” to clear the field of competitive products.
Same GLP-1 fight, different leverage
The Striker case belongs in the same conversation as the semaglutide and tirzepatide litigation, but Lilly is using a different form of leverage. Lilly’s tirzepatide cases and Novo Nordisk’s semaglutide cases largely grew out of approved drugs, shortage rules, copycat products, and whether compounders could keep operating after the shortage rationale disappeared. In many ways this approach tracks their early attacks in this space starting in 2024, which were grounded in alleged intellectual property type violations.
Retatrutide moves the fight upstream
After a federal judge declined to block FDA’s shortage determination, Lilly said the decision “marks the end of the road for mass compounding of risky, unapproved knockoffs that threaten the health and safety of Americans.” Novo Nordisk has used similar patient-safety language in the semaglutide cases, describing its litigation as targeting “illegitimate, knockoff Wegovy or Ozempic” and warning that patients should not have to “gamble with their health by using knockoff drugs made with ingredients that lack oversight and safety standards.”
Retatrutide is upstream of that fight. There is no approved reference product, no approved commercial formulation, no FDA-approved label, and no shortage-based opening. FDA’s statement is direct: “Retatrutide . . . cannot be used in compounding under federal law.” Lilly’s complaint filed today goes further: “Retatrutide cannot legally be sold for human use to anyone, anywhere, for any reason.”
Lilly’s Bio Pivot
Lilly’s own history with FDA adds, however, another layer. A company seeking FDA approval to market a new product may submit a "request for designation" asking the FDA to classify its product as a drug or biological product. In November 2023, Lilly formally asked FDA to classify retatrutide as a biological product.
"Lilly argued that retatrutide met the regulatory definition of "protein" because (1) it has a "specific, defined sequence"; (2) its chains "are associated with each other in a manner that occurs in nature"; and (3) it is an "alpha amino acid polymer that is greater than 40 amino acids in size." With respect to the third requirement, Lilly argued that "FDA should count all amino acids in retatrutide, including nonalpha amino acids, if any, in assessing protein status."
FDA strongly disagreed, concluding that retatrutide did not satisfy the regulatory definition of a “protein” and rejecting Lilly’s alternative argument that it was “analogous” to one.
"FDA also concluded that retatrutide is not "analogous to a protein" because "being greater than 40 alpha amino acids is a fundamental, defining property of a protein, which retatrutide does not have." Id. at 259. According to the agency, "it would not be appropriate for the statutory term 'analogous product' to be interpreted in a way that would include products that are specifically excluded by this final rule." Id. at 258. Adopting Lilly's argument, FDA argued, would "defeat the purpose of the bright line rule because FDA would frequently have to evaluate on a case-bycase basis the features of a particular molecule to determine if it is analogous to a protein."
Lilly sued FDA in September 2024 to push their biologic position. In September 2025, a federal district court upheld FDA’s conclusion that retatrutide does not meet the regulatory definition of a protein but rejected the agency’s reasoning on whether retatrutide could qualify as “analogous” to a protein and sent that issue back to FDA. Lilly appealed the portion it lost in February 2026. Oral argument before the Seventh Circuit is scheduled for September 24, 2026.
Meanwhile, Lilly is moving ahead. It has publicly announced plans to submit retatrutide through a Biologics License Application in Q1 2027 and says it is completing the chemistry, manufacturing, and controls package needed for that submission.
In other words, Lilly first sought biologic classification from FDA in 2023, sued the agency after FDA rejected that position, partially prevailed in district court, appealed the portion it lost, and now plans to file a BLA while that appeal remains pending. That history gives the Striker litigation a more interesting backdrop. Lilly is asking courts to stop third parties from selling retatrutide under the regulatory rules that apply today while simultaneously litigating with FDA over which regulatory framework should govern retatrutide tomorrow.
There is no legal inconsistency in doing both. Retatrutide is currently unapproved regardless of whether it ultimately proceeds as a drug or biologic. But the classification dispute has consequences beyond nomenclature. Biologic status would put retatrutide on a different FDA approval and exclusivity pathway, with potentially significant consequences for how long Lilly is protected from certain forms of competition and how future competitors could enter the market. BLA approval for reta would lock in the first true monopoly in the GLP space.
Lilly’s new state-law strategy
Lilly is not bringing a traditional IP based cases this time around. The complaint relies on unfair competition, consumer protection, and state-specific deceptive practices laws. Lilly’s theory turns on retatrutide’s current legal status: there is no FDA-approved retatrutide product and, under FDA’s current position, no lawful compounded version for human use. Lilly uses retatrutide’s status as an unapproved drug to support claims under state unfair competition, consumer-protection, and deceptive trade practices laws in Alaska, Colorado, Connecticut, North Carolina, South Carolina, Tennessee, Texas, and Washington. Lilly seeks a permanent injunction barring Striker from manufacturing, marketing, distributing, dispensing, or selling any product containing or purporting to contain retatrutide. The alleged harm also extends beyond current sales. Lilly claims that consumer experiences with unauthorized retatrutide products could damage trust in a lawful retatrutide product if one is later approved. However, some consumers already approach pharmaceutical manufacturers and the traditional healthcare system with significant skepticism, which helps explain why alternative access models have found a broad audience in the first place.
The shotgun approach of Lilly’s new approach is also interesting. These four lawsuits implicate the laws of eight states (Alaska, Colorado, Connecticut, North Carolina, South Carolina, Tennessee, Washington and Texas). By implicating the laws of these states, it hedges their lawsuit best. If even one state law is interpreted to align with their arguments, it creates a potential judicial cascade they can ride all over the country. And if they lose re one state’s law, they can contain the adverse impact to just that state.
The sentence that cuts through the noise
The complaint’s most memorable line may have little to do with competition: consumers are “injecting themselves with substances of unknown composition, purity, potency, and sterility.” The line moves the discussion away from price and access and toward the questions most likely to concern regulators, judges, clinicians, and patients: what is in the vial, where it came from, how it was made, and who verified it before injection. Those same questions—identity, sourcing, manufacturing controls, purity, and testing—were also central themes during FDA’s recent Pharmacy Compounding Advisory Committee discussions on peptides. They are legitimate questions, and ones the industry must align on to sustain responsible access. And they happen to fit the mentality of regulators everywhere. “Safety” is an effective dog whistle for all regulators and Lilly is effectively blowing it, convincing them that scores of the public are at imminent risk of harm in this space, regardless of whether there is any factual support.
Lilly is defending the market before it exists
Lilly also alleges that Striker’s sales diverted consumers from Lilly’s FDA-approved obesity medicines and harmed the future market for any approved retatrutide product. Thios exposes the early “ground and pound” legal strategy. They’re protecting something before it’s even cleared. The theory reaches beyond present lost sales to pipeline value, clinical data, future exclusivity, and public perception before launch. Lilly is entitled to use the legal and regulatory tools available to protect those interests. But the commercial consequences of those tools do not disappear simply because the litigation also raises legitimate patient-safety concerns, whether founded or not.
Flipping the script
The compounding pharmacy industry has generally argued that responsible compounding has a legitimate role when FDA-approved drugs are unavailable, while also acknowledging that retatrutide should not be compounded at present.
Lilly’s biologic fight makes that discussion more complicated. Since 2023, Lilly has actively contested the regulatory category that will govern retatrutide, including by suing FDA when the agency rejected its preferred classification. Now, while that litigation remains pending, Lilly is invoking retatrutide’s current regulatory status to challenge other businesses’ access to the molecule.
Lilly has every right to challenge FDA’s interpretation of the statute, just as it has every right to enforce laws it believes Striker violated. But the parallel is worth examining. If Lilly can seek a regulatory classification that protects their commercial best interests, doesn’t the strategy align with the Research Use Only strategy in the direct to consumer space? Both seem to game regulatory classification to their commercial benefit.
The comparison, of course, has limits. Lilly is pursuing biologic classification through the formal FDA approval system. A research supplier operating outside the human-use drug framework faces a very different intended-use analysis, but only when the RUO label is read out of context. If RUO labelling is truly mean to fill the needs of the research industry (and it’s not), then the FDA’s insistence of interpreting RUO labelling literally makes perfect sense. But if it’s read to algin with the same gaming strategy used by Lilly (and Pharma in general), then context should matter.
That said, Lilly’s own history makes it difficult to treat regulatory categorization as commercially neutral. Lilly believes FDA applied the wrong category to its molecule and has spent nearly three years trying to change it. Research-market participants likewise structure their operations around the regulatory categories they believe the FDA will apply to their products. Neither “patient protection” nor “research use only” should carry the analysis by itself. And maybe it’s time ot take a step back from “how things are done” and try to square these practices with what’s reasonable and also safety driven.
The fight over the label
The obesity-treatment market is moving faster than public understanding of the regulatory rules. Speed creates opportunity, but it also creates legal exposure. Semaglutide and tirzepatide centered the debate on drug shortages, temporary compounding flexibility, and what happens once FDA determines those shortages are resolved. Retatrutide moves the fight earlier in the product life cycle: whether an investigational molecule can be commercialized before FDA authorization, and how aggressively a manufacturer can use existing regulatory and state-law boundaries to protect the future market while approval remains pending.
“Not yet approved” does not mean “available through a workaround.” But “patient safety” should not become the phrase that shuts down every uncomfortable issue, especially when there seems to be a lack of credible evidence supporting an allegation of imminent threat to consumers. That said, Lilly may have a strong argument on retatrutide’s current legal status while also using litigation to draw the market map before anyone else reaches the field.
If the next GLP-1 market is going to be shaped by regulatory classifications before the product is even approved, the entire industry should be candid about what those classifications do. They may protect patients, but they also allocate access, exclusivity, risk, and control. And potentially drive prices sky high. Which is a large part of the reason propelling the RUO labelled industry every day!
That is the part of the Striker case worth watching.